Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

30 déc. 2014 08h00 HE | Source: BrainsWay Ltd.

Brainsway Launches Distribution Company in the U.S.

JERUSALEM, Dec. 30, 2014 (GLOBE NEWSWIRE) -- Brainsway Ltd. (TASE:BRIN) announced that in light of developments in the U.S. market, including the increased interest in Brainsway's technology and...
15 déc. 2014 08h00 HE | Source: BrainsWay Ltd.

Brainsway Receives IDE Approval From FDA for Launching Pivotal PTSD Multi-Center Trial

JERUSALEM, Dec. 15, 2014 (GLOBE NEWSWIRE) -- Brainsway Ltd. (TASE:BRIN) announced that it received an IDE (Investigational Device Exemptions) approval from the FDA for launching a Multi-Center trial...
04 déc. 2014 08h00 HE | Source: BrainsWay Ltd.

Brainsway Receives CE Approvals for Treating Multiple Sclerosis (MS), Stroke and Obsessive Compulsive Disorder (OCD)

JERUSALEM, Dec. 4, 2014 (GLOBE NEWSWIRE) -- Brainsway Ltd. (TASE:BRIN) announced that it received a CE Marketing Approval, enabling it to immediately market and sell Brainsway Deep TMS (Deep...
13 oct. 2014 09h00 HE | Source: BrainsWay Ltd.

Brainsway Wins 2014 FLC Mid-Atlantic Regional Award for Excellence in Technology Transfer

JERUSALEM, Oct. 13, 2014 (GLOBE NEWSWIRE) -- Brainsway Ltd. (TASE:BRIN) announced that its Deep TMS treatment has won the 2014 Federal Laboratory Consortium for Technology Transfer (FLC) Mid-Atlantic...
30 sept. 2014 08h39 HE | Source: BrainsWay Ltd.

Brainsway Deep TMS Brings Substantial Improvement to OCD Patients in Deep TMS Study

JERUSALEM, Sept. 30, 2014 (GLOBE NEWSWIRE) -- Brainsway Ltd. (TASE:BRIN) is pleased to report substantial improvement in OCD (Obsessive-Compulsive Disorder) patients following Brainsway Deep TMS...
05 juin 2014 15h58 HE | Source: BrainsWay Ltd.

Results Announced for Study of Major Depression Patients Who Did Not Respond to Medication Treatments

JERUSALEM, June 5, 2014 (GLOBE NEWSWIRE) -- Brainsway Ltd. (TASE:BRIN) is pleased to announce the final results for a study examining the safety and effectiveness of Brainsway's technology for...
19 déc. 2013 08h32 HE | Source: BrainsWay Ltd.

Brainsway Receives FDA Approval of IDE for Obsessive-Compulsive Disorder Study

JERUSALEM, Dec. 19, 2013 (GLOBE NEWSWIRE) -- Brainsway Ltd. (TASE:BRIN) is pleased to announce that the U.S. Food and Drug Administration ("FDA") has approved an Investigational Device Exemption...
23 sept. 2013 12h16 HE | Source: BrainsWay Ltd.

Brainsway's Deep TMS System to be Marketed and Distributed in Japan

JERUSALEM, Sept. 23, 2013 (GLOBE NEWSWIRE) -- Brainsway Ltd. (TASE:BRIN) ("Brainsway" or the "Company") is pleased to announce the execution of an agreement for the marketing and distribution of its...
11 sept. 2013 13h30 HE | Source: BrainsWay Ltd.

Brainsway Receives FDA Approval of IDE for Multi-Center Smoking Cessation Study

JERUSALEM, Sept. 11, 2013 (GLOBE NEWSWIRE) -- Brainsway Ltd. (TASE:BRIN) is pleased to announce that the U.S. Food and Drug Administration ("FDA") has approved an IDE ("Investigational Device...
04 sept. 2013 07h48 HE | Source: BrainsWay Ltd.

Brainsway Reports Positive Final Results of Study Using Deep TMS to Treat OCD

JERUSALEM, Sept. 4, 2013 (GLOBE NEWSWIRE) -- Brainsway Ltd. (TASE:BRIN) is pleased to report the final results of a clinical trial conducted at the Sheba Medical Center at Tel Hashomer to assess the...

Page précédente